Arovella Therapeutics Says FDA Accepts Investigational New Drug Application for Blood Cancer Drug Candidate

MT Newswires Live12:20

Arovella Therapeutics (ASX:ALA) said the US Food and Drug Administration (FDA) accepted its investigational new drug application for its ALA-101 drug candidate to commence first-in-human clinical trials in patients with CD19-positive non-Hodgkin's lymphoma and leukaemia, according to a Thursday Australian bourse filing.

This will allow it to conduct its phase one trial in Australia via the clinical trial notification scheme rather than the "lengthier" clinical trial application pathway, per the filing. The planned study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the candidate in patients with relapsed/refractory CD19-positive non-Hodgkin's lymphoma and leukaemia.

Its shares rose 2% in recent trading on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607977190?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-29 12:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607977190","market":"us","top_or_hot":-1,"title":"Arovella Therapeutics Says FDA Accepts Investigational New Drug Application for Blood Cancer Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ARVEF\">Arovella Therapeutics</a> (ASX:ALA) said the US Food and Drug Administration (FDA) accepted its investigational new drug application for its ALA-101 drug candidate to commence first-in-human clinical trials in patients with CD19-positive non-Hodgkin's lymphoma and leukaemia, according to a Thursday Australian bourse filing.</p><p>This will allow it to conduct its phase one trial in Australia via the clinical trial notification scheme rather than the \"lengthier\" clinical trial application pathway, per the filing. The planned study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the candidate in patients with relapsed/refractory CD19-positive non-Hodgkin's lymphoma and leukaemia.</p><p>Its shares rose 2% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arovella Therapeutics Says FDA Accepts Investigational New Drug Application for Blood Cancer Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArovella Therapeutics Says FDA Accepts Investigational New Drug Application for Blood Cancer Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-29 12:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ARVEF\">Arovella Therapeutics</a> (ASX:ALA) said the US Food and Drug Administration (FDA) accepted its investigational new drug application for its ALA-101 drug candidate to commence first-in-human clinical trials in patients with CD19-positive non-Hodgkin's lymphoma and leukaemia, according to a Thursday Australian bourse filing.</p><p>This will allow it to conduct its phase one trial in Australia via the clinical trial notification scheme rather than the \"lengthier\" clinical trial application pathway, per the filing. The planned study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the candidate in patients with relapsed/refractory CD19-positive non-Hodgkin's lymphoma and leukaemia.</p><p>Its shares rose 2% in recent trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2607977190","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607977190","pubTimestamp":1769660439,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arovella Therapeutics (ASX:ALA) said the US Food and Drug Administration (FDA) accepted its investigational new drug application for its ALA-101 drug candidate to commence first-in-human clinical tria","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","BK4539":"次新股","BK4139":"生物科技","ALA.AU":"AROVELLA THERAPEUTICS LTD","LENZ":"Therapeutics","BK4007":"制药"},"translate_title":"Arovella Therapeutics表示FDA接受血癌候选药物的研究性新药申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALA.AU":1,"LENZ":1.5},"content_text":"Arovella Therapeutics (ASX:ALA) said the US Food and Drug Administration (FDA) accepted its investigational new drug application for its ALA-101 drug candidate to commence first-in-human clinical trials in patients with CD19-positive non-Hodgkin's lymphoma and leukaemia, according to a Thursday Australian bourse filing.This will allow it to conduct its phase one trial in Australia via the clinical trial notification scheme rather than the \"lengthier\" clinical trial application pathway, per the filing. The planned study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the candidate in patients with relapsed/refractory CD19-positive non-Hodgkin's lymphoma and leukaemia.Its shares rose 2% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607977190","isCrawlerRequest":true}